
CLAIMS

1. Use of a compound of the formula:



,

in the manufacture of a medicament for treating renal/kidney disease (RKD), insulin resistance, endothelial dysfunction, fatty liver disease, or cardiovascular disease (CVD), in a subject.

2. The use of claim 1, wherein the medicament is for treating RKD in the subject.

3. The use of claim 1, wherein the medicament is in treating insulin resistance in the subject.

4. The use of claim 1, wherein the medicament is for treating endothelial dysfunction in the subject.

5. The use of claim 1, wherein the medicament is for treating CVD in the subject.

6. The use of claim 1, wherein the medicament is for treating fatty liver disease in the subject.

7. The use according to any one of claims 1-6, wherein the subject is a human.

8. The use according to any one of claims 1-7, wherein at least a portion of the compound is present as a crystalline form having an X-ray diffraction pattern (CuKα) comprising significant diffraction peaks at about 8.8, 12.9, 13.4, 14.2 and 17.4° 2θ.

9. The use according to any one of claims 1-7, wherein at least a portion of the compound is present as an amorphous form having an X-ray diffraction pattern (CuKα) with a halo peak at approximately 13.5° 2θ, and a T_g from 120 °C to 135 °C.

10. The use of claim 9, wherein the T_g is from 125°C to 130°C.

11. The use according to any one of claims 1-10, wherein the medicament is formulated for oral, intraarterial, or intravenous administration.


12. The use according to any one of claims 1-10, wherein the medicament is formulated as a hard or soft capsule or a tablet.

13. The use according to any one of claims 1-10, wherein the medicament is formulated as a polymer dispersion.

14. The use according to any one of claims 1-10, wherein the medicament is formulated with a methacrylic acid/ethyl acrylate copolymer as an excipient.

CLAIMS

1. Use of a compound of the formula:



in the manufacture of a medicament for use in treating renal/kidney disease (RKD), insulin resistance, diabetes, endothelial dysfunction, fatty liver disease, or cardiovascular disease (CVD), in a subject.

2. The use of claim 1, wherein the medicament is for use in treating RKD in the subject.

3. The use of claim 1, wherein the medicament is for use in treating insulin resistance in the subject.

4. The use of claim 1, wherein the medicament is for use in treating diabetes in the subject.

5. The use of claim 4, wherein the medicament also effectively treats one or more complications associated with diabetes in the subject, wherein the complications are selected from the group consisting of obesity, hypertension, atherosclerosis, coronary heart disease, stroke, peripheral vascular disease, nephropathy, neuropathy, myonecrosis, retinopathy and metabolic syndrome (syndrome X).

6. The use of claim 1, wherein the medicament is for use in treating endothelial dysfunction in the subject.

7. The use of claim 1, wherein the medicament is for use in treating CVD in the subject.

8. The use of claim 1, wherein the medicament is for use in treating fatty liver disease in the subject.

9. The use according to any one of claims 1-8, wherein the subject is a human.

10. The use according to any one of claims 1-9, wherein at least a portion of the compound is present as a crystalline form having an X-ray diffraction pattern (CuKα) comprising significant diffraction peaks at about 8.8, 12.9, 13.4, 14.2 and 17.4° 2θ.

11. The use of claim 10, wherein the X-ray diffraction pattern (CuKα) is substantially as shown in FIG. 12A or FIG. 12B.

12. The use according to any one of claims 1-9, wherein at least a portion of the compound is present as an amorphous form having an X-ray diffraction pattern (CuKα) with a halo peak at approximately 13.5° 2θ, substantially as shown in FIG. 12C, and a T_g from 120 °C to 135 °C.

13. The use of claim 12, wherein the T_g is from 125°C to 130°C.

14. The use according to any one of claims 1-13, wherein the compound is formulated for oral, intraarterial, or intravenous administration.

15. The use according to any one of claims 1-13, wherein the compound is formulated as a hard or soft capsule or a tablet.

16. The use according to any one of claims 1-13, wherein the compound is formulated as a polymer dispersion.

17. The use according to any one of claims 1-13, wherein the compound is formulated with a methacrylic acid/ethyl acrylate copolymer as an excipient.